Immunotherapy plus chemo, then radiation, for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your cervical cancer diagnosis was confirmed by lab testing, and the type is adenocarcinoma, adenosquamous, or squamous
- Your cancer stage matches FIGO 2018 Ib3 to IIIc2, and you have at least one measurable tumor spot on scans
- You have never had cancer treatment yet, and you are expected to live at least 3 months
- Your overall health is strong enough for treatment (ECOG 0–1), and key blood counts are adequate
- Your liver, kidney, and heart tests are within required limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.
This trial tests giving a combination of an immunotherapy drug (QL1706) and two chemotherapy drugs (cisplatin and paclitaxel) before surgery for cervical cancer. The goal is to shrink the tumor to make surgery more effective and improve outcomes.
This trial tests a combination of an immunotherapy drug (AK104) with internal radiation therapy (I-125 brachytherapy) for cervical cancer that has come back or spread. The goal is to see if this combination can control the cancer and improve survival.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.